China News Online, January 23 (Reporter Chen Jing) After 14 years of continuous efforts, the innovative oncology drug Sutaida® (Sofatinib Capsule) independently developed by Chinese pharmaceutical companies was officially launched on the 23rd.
It is understood that Sutaida® is a new type of oral tyrosine kinase inhibitor, which has been approved by the National Medical Products Administration for the treatment of non-pancreatic neuroendocrine tumors.
Unlike traditional anti-tumor drugs, Sutaida® has both "anti-angiogenesis" and "immune regulation" dual anti-tumor mechanisms, which not only inhibit tumor angiogenesis, but also activate the body's immune function.
In an interview with reporters on the 23rd, Chen Kaixian, academician of the Chinese Academy of Sciences, stated that the launch of Sutaida® not only provides drug solutions for targeted treatment of non-pancreatic neuroendocrine tumors in China, but also shows that Chinese innovative drugs are adopting cutting-edge innovative research concepts and rigorous standards. The research and development process accelerates to benefit Chinese patients and to the world.
"
Chen Kaixian said that for a long period of time in the past, China's independent research and development capabilities for new drugs were weak and it was impossible to get rid of its dependence on imported drugs.
In the past ten or twenty years, China's new drug research and development capabilities and output have made very rapid progress. From 2018 to 2020, China has continuously approved new drugs independently developed for the market.
This means that China's drug R&D and innovation capabilities are rapidly improving.
Neuroendocrine tumors (NET) are a type of tumors that originate from neuroendocrine cells, most commonly in the stomach, intestines, pancreas and lungs.
Among them, non-pancreatic NET accounts for about 90%.
Professor Wang Liwei from the Department of Oncology, Renji Hospital, Shanghai Jiaotong University School of Medicine, said on the same day: “Previously, the treatment options for NET patients were very limited, and more innovative therapies are urgently needed to meet the unfulfilled needs of patients.
During the interview, the reporter learned that the relevant clinical research reality showed that the median progression-free survival (PFS) of patients in the Sutaida® treatment group was significantly prolonged and the safety was good.
In the view of Professor Wang Liwei, Sutaida® is expected to drive the reform of China's NET clinical practice guidelines and promote the vigorous development of China's innovative drugs.
During the interview, the reporter learned that in the future, Sofatinib, as a Chinese innovative drug, is expected to go global, bringing more choices and good news to a large number of overseas patients.
In December 2020, Sofatinib was approved for listing in China. In the same month, it also began rolling submission of new drug marketing applications to the US FDA, and is expected to be approved for listing in the United States in 2021.
It is understood that companies will also submit new drug listing applications to Europe.
(Finish)